Factor X/Xa Polyclonal Antibody, Invitrogen™

Description

Recommended positive controls: HeLa, human F10-transfected 293T cells, GL261, C8D30. Predicted reactivity: Mouse (84%), Rabbit (81%), Rhesus Monkey (95%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Factor X undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity.